Erectile Dysfunction Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2 Dose Ranging Trial To Assess The Safety and Efficacy of DA-8159 Tablets in Male Subjects With Erectile Dysfunction.
Verified date | February 2007 |
Source | Dong-A PharmTech Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of subjects with erectile dysfunction (ED).
Status | Completed |
Enrollment | 300 |
Est. completion date | June 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 19 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Is male and at least 19 years of age. 2. Has a stable monogamous relationship for at least 6 months with a consenting female partner (vaginal intercourse is a required study activity). 3. Provides written informed consent. 4. The subject’s female partner provides written informed consent. 5. Has a history of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration. The investigator will record the etiology of the ED (organic, psychogenic or mixed). 6. Has scored between 6-25 for the Erectile Function domain score (Questions Number 1-5, 15) at both Visits 1 & 2. 7. Completes least four diary entries by Visit 2, showing at least 4 attempts at sexual intercourse with a 50% or greater failure rate in achieving or in maintaining an erection sufficient to complete intercourse (defined as answering “no” to SEP questions #2 or #3). 8. The subject’s partner is not pregnant or lactating and both subject and partner agree to the use of a medically acceptable form of birth control. Exceptions would be subjects with a vasectomy or partners that are post menopausal, and partners that have had a tubal ligation or hysterectomy. Exclusion Criteria: 1. Has a history of stroke, myocardial infarction, or coronary artery disease within the past 6 months. 2. Has a history of cardiac failure, angina, or life-threatening arrhythmia within the past 6 months. 3. Is taking nitrate medication in any form(Appendix 7) 4. Is taking alpha blockers. 5. Has a clinically significant abnormal laboratory value as determined by the principal investigator. 6. Has a history of uncontrolled diabetes (HbA1c>9%). 7. Has a history of proliferative diabetic retinopathy. 8. Has a history of spinal cord injury or a radical prostatectomy or radical pelvic surgery. 9. Has a supine blood pressure lower than 90/50mmHg or uncontrolled hypertension higher than 170/100mmHg. 10. Has a anatomical deformity of the penis such as severe penile fibrosis or Peyronie’s disease. 11. Has a thyroid stimulating hormone (TSH) level lower than 30% of LLN. 12. Has erectile dysfunction caused by neurological or endocrine factors such as hyperprolactinemia or low serum testosterone levels (<300 ng/dl). 13. Has hepatic impairment (GOT, GPT levels > 3 x ULN). 14. Has renal impairment (serum creatinine = 2.5mg/dl). 15. Has a history of hematological disorder such as bleeding disorder or a risk of GI bleeding such as peptic ulceration. 16. Has a history of retinitis pigmentosa. 17. Has a history of sickle cell disease, multiple myeloma, leukemia or any other disorders that may cause priapism. 18. Has a history of significant psychiatric disorder. 19. Has a history of central nervous system disorders such as stroke, transient ischemic attacks, or spinal cord injury. 20. Has a history of drug abuse (alcohol, marijuana, cocaine, or opiates). 21. Has a known sensitivity to drugs especially to phosphodiesterase type 5 inhibitors such as Viagra, Cialis or Levitra. 22. Has used other erectile dysfunction therapies including nutraceutical and herbal products within 14 days prior to entering into this study. 23. Is using concomitant medications that are known or suspected to interact with PDE 5 inhibitors such as the following: 1. Antibacterial: erythromycin 2. Antifungals: itraconazole, ketoconazole 3. Antivirals: ritonavir, saquinavir, amprenavir, indinavir, nelfinavir 4. H2 receptor antagonist: cimetidine 5. Anticoagulants, androgens, trazodone 24. Have other sexual disorders such as hypoactive sexual desire. 25. Have previously failed to respond to PDE-5 inhibitors such as Viagra, Cialis or Levitra. 26. Have a major illness that in the opinion of the investigator would interfere with the conduct of the study. 27. Has not participated in a clinical drug study within the last 30 days prior to entering this study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Urology Research Options | Aurora | Colorado |
United States | South Florida Medical Research | Aventura | Florida |
United States | The Male Clinic | Beverly Hills | California |
United States | Northeast Indiana Research, LLC | Fort Wayne | Indiana |
United States | Accumed Research Associates | Garden City | New York |
United States | Drs. Werner, Murdock & Francis, P.A. , Urology Associates | Greenbelt | Maryland |
United States | Medical Affiliated Research Center | Huntsville | Alabama |
United States | South Orange County | Laguna Woods | California |
United States | California Profession Research | Newport Beach | California |
United States | Florida Foundation for Healthcare Research | Ocala | Florida |
United States | University Urological Researcgh Institute | Providence | Rhode Island |
United States | Urology San Antonio Research | San Antonio | Texas |
United States | West Coast Clinical Research | Tarzana | California |
United States | Connecticut Clinical Research Center | Waterbury | Connecticut |
United States | Center for Urologic Research of Western New York | Williamsville | New York |
Lead Sponsor | Collaborator |
---|---|
Dong-A PharmTech Co., Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy end points are: | |||
Primary | the change in score (baseline to Visit 5) for the Erectile Function domain score of the IIEF; | |||
Primary | change in response, relative to baseline, for sexual encounter profile (SEP) question 2, and | |||
Primary | change in response, relative to baseline, for SEP question 3. | |||
Primary | Safety will be assessed by monitoring adverse events and changes in vital signs, clinical laboratory test results, 12-lead ECG, and physical examinations. | |||
Secondary | The study has several secondary efficacy measurements including: | |||
Secondary | changes in the satisfaction of intercourse, orgasmic function, sexual desire and overall satisfaction domains of the IIEF, | |||
Secondary | changes from baseline in SEP questions 1, 4 and 5; | |||
Secondary | the global assessment questionnaire (GAQ), and | |||
Secondary | changes from baseline in patient self assessment questionnaire (PSAE) scores. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |